Drug-delivery therapy

TARGETED DRUG-DELIVERY THERAPY OF TUMORS USING L.C.M. 

In view of the detailed published information available on the presence, functional characteristics, and localization of scavenger receptor populations in atherosclerotic lesions (cf. above) as well as the known structural similarity between modified LDL and LCM (cf. Sections 12.1, 14.2.2-14.2.2(ii)), LCM-directed drug delivery to atherosclerotic lesions may offer a means for targeted drug-delivery therapy of atherosclerosis. 

Poly(carbonates) also have been developed for drug-delivery therapies [47,48]. Poly(DTH carbonate) microspheres have been utilized for innacranial controlled release of dopamine [40,49]. These microspheres do not exhibit a burst release phase and release dopamine at a controlled rate, where 15% of the total drug is released over a period of 180 days with an average dose of l-2pg/day [49]. 

A variety of other clinically important infections, such as brucellosis, listeriosis, salmonellosis, and various Mycobacterium infections, are of interest as these are often localized in organs rich in MPS cells. Liposome encapsulation has been demonstrated to improve therapeutic indices of several drugs in a number of infectious models. The natural avidity of macrophages for liposomes can also be exploited in the application of the vesicles as carriers of immunomodulators to activate these cells to an microbicidal, antiviral, or tumoricidal state. These studies were recently reviewed by Emmen and Storm (1987), Popescu et al. (1987), and Alving (1988). In addition to the treatment of "old" infectious diseases, the concept of MPS-directed drug delivery is of considerable interest for the therapy AIDS, possibly enabling control of human immunodeficiency virus replication in human macrophages. 

The stndy and preparation of hollow capsules has attracted considerable attention in recent years. Hollow capsules are of immense interest in a long list of potential applications. These inclnde drug delivery, gene therapy, catalysis, waste removal, acoustic insulation, piezoelectric transducers, and functional materials [14],... 

Evaluate therapy on a regular basis. Assess the patient s control of asthma by evaluating symptoms, PEF diary entries, and rescue medication use. Step long-term control therapy up or down based on these parameters. Before stepping up therapy, reassess the patient s inhaler technique to assure appropriate drug delivery. 

Inhaled antibiotics are typically stopped during an acute exacerbation requiring IV therapy. Drug delivery is reduced... 

Notwithstanding the plaints above, the last question must be discussed can a delivery system be used to overcome conditions imposed by the biological system (excluding those posed by the route of administration) to achieve optimized therapy Two major approaches to this end have been proposed regional drug delivery and targeted drug delivery. 

When the target of therapy lies beneath the stratum corneum, topical drug delivery is more difficult and... 

Drug delivery to the respiratory tract has been characterized in the past decade by an increase in knowledge of drug droplet or particle manufacture, behavior, aerosol dispersion, lung deposition and clearance. The number of diseases for which aerosol therapy may be applicable has increased dramatically. The pharmaceutical scientist is no longer limited to pulmonary diseases as therapeutic targets. Substantial progress has been made in every area of pharmaceutical aerosol science, and it is anticipated that this will ultimately lead to many new therapies. 

Osmotic systems have application in pharmacological studies, implantation therapies, and oral drug delivery. 

The potential of liposomes in oral drug delivery has been largely disappointing. However, the use of polymer-coated, polymerized, and microencapsulated liposomes have all increased their potential for oral use [63], and it predicted that a greater understanding of their cellular processing will ultimately lead to effective therapies for oral liposomes. 

T. Kato, Encapsulated drugs in targeted cancer therapy, in Controlled Drug Delivery (S. D. Bruck. ed.), CRC Press, Boca Raton, FL, 1983, p. 189. 

The critical void in pediatric drug therapy now lies in effective drug-delivery systems. Some inroads have been made in the manufacturing of pediatric dosing systems, particularly OTC preparations. There needs to be a redirection of the focus in nonparenteral drug formulations towards pediatric dosage forms with proven stability and bioavailability that can be easily and accurately administered to infants and children. 

A composite scaffold drug delivery system (CS-DDS) for osteoarticular tuberculosis therapy has been prepared by loading bi-component drugs into a... 

---